Pathogenesis and Therapy of Rheumatoid Arthritis

Conference paper
Part of the Ernst Schering Foundation Symposium Proceedings book series (SCHERING FOUND, volume 2006/1)


Rheumatoid arthritis is a chronic disabling disease affecting at least 1% of the population on a worldwide basis. Research aimed at understanding the pathogenesis of this disease led to the identification of TNFα as a major pro-inflammatory cytokine expressed in the inflamed joints of patients with rheumatoid arthritis. Subsequently, in vitro studies provided evidence to suggest that TNFα played an important role in driving the expression of additional pro-inflammatory cytokines, such as IL-1, GM-CSF, IL-6, and IL-8, in synovial cell cultures. Another important finding that confirmed the pathological significance of TNFα was that mice genetically engineered to overexpress TNFα spontaneously developed arthritis. Subsequently, the therapeutic effect TNFα blockade was tested in animal models prior to clinical trials in human patients, which provided unequivocal verification of the validity of TNFα as a therapeutic target. Anti-TNFα therapy is now accepted as a fully-validated treatment modality for rheumatoid arthritis.


Vascular Endothelial Growth Factor Rheumatoid Arthritis Patient Vascular Endothelial Growth Factor Level Rheumatoid Arthritis Synovium Human Rheumatoid Arthritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by the Arthritis Research Campaign (ARC) of Great Britain.


  1. Afuwape AO, Kiriakidis S, Paleolog EM (2002) The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis. Histol Histopathol 17:961–72PubMedGoogle Scholar
  2. Albano SA, Santana-Sahagun E, Weisman MH (2001) Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum 31:146–59PubMedCrossRefGoogle Scholar
  3. Alvaro-Garcia JM, Zvaifler NJ, Brown CB, Kaushansky L, Firestein GS (1991) Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and TNFα. J Immunol 146:3365–3371Google Scholar
  4. Anonymous (1978) Reduction in incidence of rheumatoid arthritis associated with oral contraceptives. Royal College of General Practitioners' Oral Contraception Study. Lancet 1:569–571Google Scholar
  5. Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN, Paleolog EM (2001) Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 44:2055–2064PubMedCrossRefGoogle Scholar
  6. Banerjee S, Wei BY, Hillman K, Luthra HS, David CS (1988) Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor antibody. J Immunol 141:1150–1154PubMedGoogle Scholar
  7. Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M (1983) Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 2:1115–1119PubMedCrossRefGoogle Scholar
  8. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M (1989) Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244–247PubMedCrossRefGoogle Scholar
  9. Brennan FM, Zachariae CO, Chantry D, Larsen CG, Turner M, Maini RN, Matsushima K, Feldmann M (1990) Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol 20:2141–2144PubMedCrossRefGoogle Scholar
  10. Brennan FM, Gibbons DL, Cope AP, Katsikis P, Maini RN, Feldmann M (1995) TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action. Scand J Immunol 42:158–165PubMedCrossRefGoogle Scholar
  11. Brennan P, Bankhead C, Silman A, Symmons D (1997) Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident case-control study. Semin Arthritis Rheum 26:817–823PubMedCrossRefGoogle Scholar
  12. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M (1988) Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol 73:449–455PubMedGoogle Scholar
  13. Butler DM, Maini RN, Feldmann M, Brennan FM (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 6:225–230PubMedGoogle Scholar
  14. Buzas EI, Hollo K, Rubliczky L, Garzo M, Nyirkos P, Glant TT (1993) Effect of pregnancy on proteoglycan-induced progressive polyarthritis in BALB/c mice: remission of disease activity. Clin Exp Immunol 94:252–260PubMedCrossRefGoogle Scholar
  15. Choy EH, Kinsley GH, Panayi GS (1998) Monoclonal antibody therapy in rheumatoid arthritis. Br J Rheumatol 37:484–490PubMedCrossRefGoogle Scholar
  16. Chu CQ, Field M, Abney E, Zheng RQ, Allard S, Feldmann M, Maini RN (1991) Transforming growth factor-beta 1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol 86:380–386PubMedCrossRefGoogle Scholar
  17. Cohen S, Katsikis PD, Chu CQ, Thmssen H, Webb LMC, Maini RN, Londei M, Feldmann M (1995) High IL-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthritis Rheum 38:946–952PubMedCrossRefGoogle Scholar
  18. Cooper SM, Sriram S, Ranges GE (1988) Suppression of murine collagen-induced arthritis with monoclonal anti-Ia antibodies and augmentation with IFN-gamma. J Immunol 141:1958–1962PubMedGoogle Scholar
  19. Cope AP (2003) Exploring the reciprocal relationship between immunity and inflammation in chronic inflammatory arthritis. Rheumatology (Oxford) 42:716–731CrossRefGoogle Scholar
  20. Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, Brennan FM, Maini RN, Wallach D, Feldmann M (1992) Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 35:1160–1169PubMedCrossRefGoogle Scholar
  21. Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, Maini RN, Feldmann M (1994) Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94:749–760PubMedCrossRefGoogle Scholar
  22. Da Silva JA, Spector TD (1992) The role of pregnancy in the course and aetiology of rheumatoid arthritis. Clin Rheumatol 11:189–194PubMedCrossRefGoogle Scholar
  23. Deleuran BW, Chu CQ, Field M, Brennan FM, Katsikis P, Feldmann M, Maini RN (1992) Localization of interleukin-1α, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 31:801–809PubMedCrossRefGoogle Scholar
  24. Deroo BJ, Korach KS (2006) Estrogen receptors and human disease. J Clin Invest 116:561–570PubMedCrossRefGoogle Scholar
  25. Drossaers-Bakker KW, Zwinderman AH, van Zeben D, Breedveld FC, Hazes JM (2002) Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis. Ann Rheum Dis 61:405–408PubMedCrossRefGoogle Scholar
  26. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200:277–285PubMedCrossRefGoogle Scholar
  27. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor α. Arthritis Rheum 36:1681–1690PubMedCrossRefGoogle Scholar
  28. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smollen JS, Leeb B, Breedfeld FC, Macfarlane JD, Bijl H, Woody JN (1994a) Treatment with a chimaeric monoclonal antibody to tumour necrosis factor α suppresses disease activity in rheumatoid arthritis: results of a multi-centre, randomised, double blind trial. Lancet 344:1105–1110PubMedCrossRefGoogle Scholar
  29. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN (1994b) Repeated therapy with a monoclonal antibody to tumour necrosis factor α in patients with rheumatoid arthritis. Lancet 344:1125–1127PubMedCrossRefGoogle Scholar
  30. Feldmann M, Maini RN (2001) Anti-TNFα therapy in rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163–196PubMedCrossRefGoogle Scholar
  31. Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 14:397–440CrossRefGoogle Scholar
  32. Feldmann M, Brennan F, Williams RO, Maini RN (2003) Definition of TNFα as a therapeutic target for rheumatoid arthritis. In: Moreland LW, Emery P (eds) TNFα inhibition in the treatment of rheumatoid arthritis. Martin Dunitz, London, pp 1–22Google Scholar
  33. Goldschmidt TJ, Holmdahl R (1991) Anti-T cell receptor antibody treatment of rats with established autologous collagen-induced arthritis: suppression of arthritis without reduction of anti-type II collagen autoantibody levels. Eur J Immunol 21:1327–1330PubMedCrossRefGoogle Scholar
  34. Hanafusa T, Pujol-Borrell R, Chiovato L, Russell RCG, Doniach D, Bottazzo GF (1983) Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease: relevance for autoimmunity. Lancet ii:1111–1115Google Scholar
  35. Harris HA, Albert LM, Leathurby Y, Malamas MS, Mewshaw RE, Miller CP, Kharode YP, Marzolf J, Komm BS, Winneker RC, Frail DE, Henderson RA, Zhu Y, Keith JC Jr (2003) Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 144:4241–4249PubMedCrossRefGoogle Scholar
  36. Harrison BJ, Silman AJ, Wiles NJ, Scott DG, Symmons DP (2001) The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis. Arthritis Rheum 44:323–330PubMedCrossRefGoogle Scholar
  37. Hasler F, van de Putte L, Baudin M, Lodin E, Durrwell L, McAuliffe T, van de Auwera P (1996) Chronic TNF neutralization (up to 1 year) by lenercept (TNFR 55 IgG1, Ro 45–2081) in patients with rheumatoid arthritis: results from open label extension of a double blind single-dose phase I study. Arthritis Rheum 39:S243Google Scholar
  38. Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM (1998) Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 41:1388–1397PubMedCrossRefGoogle Scholar
  39. Hirahara F, Wooley PH, Luthra HS, Coulam CB, Griffiths MM, David CS (1986) Collagen-induced arthritis and pregnancy in mice: the effects of pregnancy on collagen-induced arthritis and the high incidence of infertility in arthritic female mice. Am J Reprod Immunol Microbiol 11:44–54PubMedGoogle Scholar
  40. Hirohata S, Sakakibara J (1999) Angioneogenesis as a possible elusive triggering factor in rheumatoid arthritis. Lancet 353:1331PubMedCrossRefGoogle Scholar
  41. Hopkins SJ, Meager A (1988) Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. Clin Exp Immunol 73:88–92PubMedGoogle Scholar
  42. Hutchinson D, Shepstone L, Moots R, Lear JT, Lynch MP (2001) Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Ann Rheum Dis 60:223–227PubMedCrossRefGoogle Scholar
  43. Janossy G, Panayi G, Duke O, Bofill M, Poulter LW, Goldstein G (1981) Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet 2:839–842PubMedCrossRefGoogle Scholar
  44. Jansson L, Holmdahl R (1989) Oestrogen induced suppression of collagen arthritis. IV: Progesterone alone does not affect the course of arthritis but enhances the oestrogen-mediated therapeutic effect. J Reprod Immunol 15:141–150PubMedCrossRefGoogle Scholar
  45. Jansson L, Holmdahl R (1992) Oestrogen-induced suppression of collagen arthritis; 17β-oestradiol is therapeutically active in normal and castrated F1 hybrid mice of both sexes. Clin Exp Immunol 89:446–451PubMedCrossRefGoogle Scholar
  46. Jansson L, Holmdahl R (2001) Enhancement of collagen-induced arthritis in female mice by estrogen receptor blockage. Arthritis Rheum 44:2168–2175PubMedCrossRefGoogle Scholar
  47. Jansson L, Mattsson A, Mattsson R, Holmdahl R (1990) Estrogen induced suppression of collagen arthritis. V: Physiological level of estrogen in DBA/1 mice is therapeutic on established arthritis, suppresses anti-type II collagen T-cell dependent immunity and stimulates polyclonal B-cell activity. J Autoimmun 3:257–270PubMedCrossRefGoogle Scholar
  48. Jansson L, Olsson T, Holmdahl R (1994) Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice. J Neuroimmunol 53:203–207PubMedCrossRefGoogle Scholar
  49. Karlson EW, Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH (1999) A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum 42:910–917PubMedCrossRefGoogle Scholar
  50. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025–4031PubMedGoogle Scholar
  51. Klareskog L, Forsum U, Scheynius A, Kabelitz D, Wigzell H (1982) Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci USA 79:3632–3636PubMedCrossRefGoogle Scholar
  52. Londei M, Lamb JR, Bottazzo GF, Feldmann M (1984) Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature 312:639–641PubMedCrossRefGoogle Scholar
  53. Londei M, Bottazzo GF, Feldmann M (1985) Human T-cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells. Science 228:85–89PubMedCrossRefGoogle Scholar
  54. Malyak M, Swaney RE, Arend WP (1993) Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Arthritis Rheum 36:781–789PubMedCrossRefGoogle Scholar
  55. Mathers D, Russell A (1990) Adjuvant arthritis in the rat during pregnancy. Clin Exp Rheumatol 8:289–292PubMedGoogle Scholar
  56. Mattsson R, Mattsson A, Holmdahl R, Whyte A, Rook GA (1991) Maintained pregnancy levels of oestrogen afford complete protection from post-partum exacerbation of collagen-induced arthritis. Clin Exp Immunol 85:41–47PubMedCrossRefGoogle Scholar
  57. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E (2000) Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 80:1195–1205PubMedCrossRefGoogle Scholar
  58. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM (1997a) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141–147PubMedCrossRefGoogle Scholar
  59. Moreland LW, Heck LW, Koopman WJ (1997b) Biologic agents for treating rheumatoid arthritis. Arthritis Rheum 40:397–409PubMedCrossRefGoogle Scholar
  60. Nelson JL, Ostensen M (1997) Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am 23:195–212PubMedCrossRefGoogle Scholar
  61. O'Garra A, Murphy K (1993) T-cell subsets in autoimmunity. Curr Opin Immunol 5:880–886PubMedCrossRefGoogle Scholar
  62. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN (1998) Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41:1258–1265PubMedCrossRefGoogle Scholar
  63. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W (1992) Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77:510–514PubMedGoogle Scholar
  64. Powrie F, Correa-Oliveira R, Mauze S, Coffman RL (1994) Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 179:589–600PubMedCrossRefGoogle Scholar
  65. Ranges GE, Sriram S, Cooper SM (1985) Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T. J Exp Med 162:1105–1110PubMedCrossRefGoogle Scholar
  66. Rooney M, Condell D, Quinlan W, Daly L, Whelan A, Feighery C, Bresnihan B (1988) Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 31:956–963PubMedCrossRefGoogle Scholar
  67. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25) Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151–1164PubMedGoogle Scholar
  68. Sheehan KC, Ruddle NH, Schreiber RD (1989) Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol 142:3884–3893PubMedGoogle Scholar
  69. Shevach EM (2000) Regulatory T cells in autoimmmunity. Annu Rev Immunol 18:423–449PubMedCrossRefGoogle Scholar
  70. Silman AJ, Pearson JE (2002) Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 4(Suppl 3):S265–S272PubMedCrossRefGoogle Scholar
  71. Silman A, Kay A, Brennan P (1992) Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum 35:152–155PubMedCrossRefGoogle Scholar
  72. Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, Ollier WE (1993) Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 32:903–907PubMedCrossRefGoogle Scholar
  73. Sivakumar B, Harry LE, Paleolog EM (2004) Modulating angiogenesis: more vs less. JAMA 292:972–977PubMedCrossRefGoogle Scholar
  74. Sumariwalla PF, Cao Y, Wu HL, Feldmann M, Paleolog EM (2003) The angiogenesis inhibitor protease-activated kringles 1–5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther 5:R32–R39PubMedCrossRefGoogle Scholar
  75. Symons JA, Wood NC, Di Giovine FS, Duff GW (1988) Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity IL-1 and IL-2 inhibition. J Immunol 141:2612–2618PubMedGoogle Scholar
  76. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, Feldmann M, Maini RN (2000) Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 43:38–47PubMedCrossRefGoogle Scholar
  77. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA (1992) Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 89:7375–7379PubMedCrossRefGoogle Scholar
  78. Todd I, Londei M, Feldmann M, Bottazzo GF (1985) Role of MHC class II molecules and of autoantigens in the pathogenesis of human autoimmune endocrine diseases. In: Milgrom F, Abeyounis CJ, Albini B (eds) Antibodies: protective, destructive and regulatory role. Karger, Basel, pp 66–76Google Scholar
  79. Van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS (2004) CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 50:2775–2785PubMedCrossRefGoogle Scholar
  80. Waites GT, Whyte A (1987) Effect of pregnancy on collagen-induced arthritis in mice. Clin Exp Immunol 67:467–476PubMedGoogle Scholar
  81. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259PubMedCrossRefGoogle Scholar
  82. Whyte A, Waites GT (1987) Levels of serum amyloid P-component associated with pregnancy and collagen-induced arthritis in DBA/1 (H-2q) mice. J Reprod Immunoly 12:155–159CrossRefGoogle Scholar
  83. Williams RO, Whyte A (1989) A comparison of anti-type II collagen antibody titres and isotype profiles in pregnant and virgin DBA/1 mice with collagen- induced arthritis. J Reprod Immunol 15:229–239PubMedCrossRefGoogle Scholar
  84. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784–9788PubMedCrossRefGoogle Scholar
  85. Williams RO, Ghrayeb J, Feldmann M, Maini RN (1995) Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD. Immunology 84:433–439PubMedGoogle Scholar
  86. Wooley PH, Dutcher J, Widmer MB, Gillis S (1993) Influence of a recombinant human soluble tumour necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 151:6602–6607PubMedGoogle Scholar
  87. Xu WD, Firestein GS, Taetle R, Kaushansky K, Zvaifler NJ (1989) Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest 83:876–882PubMedCrossRefGoogle Scholar
  88. Yoshino S, Cleland LG, Mayrhofer G (1991) Treatment of collagen-induced arthritis in rats with a monoclonal antibody against the alpha/beta T cell antigen receptor. Arthritis Rheum 34:1039–1047PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Kennedy Institute of Rheumatology DivisionImperial College LondonLondonUK

Personalised recommendations